BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27816693)

  • 1. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
    Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
    Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
    Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
    Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
    J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
    Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
    Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
    Pokorná Z; Kollárová-Brázdová P; Lenčová-Popelová O; Jirkovský E; Kubeš J; Mazurová Y; Adamcová M; Holečková M; Palička V; Šimůnek T; Štěrba M
    Clin Sci (Lond); 2022 Jan; 136(1):139-161. PubMed ID: 34878093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
    Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
    Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
    Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.
    Simůnek T; Sterba M; Popelová O; Kaiserová H; Adamcová M; Hroch M; Hasková P; Ponka P; Gersl V
    Br J Pharmacol; 2008 Sep; 155(1):138-48. PubMed ID: 18536744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
    Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
    Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
    Li W; Xu B; Xu J; Wu XL
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
    Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
    Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
    Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
    Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antioxidants in anthracycline cardiotoxicity.
    Hideg K; Kálai T
    Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.